Company intelligence
Harbour BioMed
#DrugDiscovery #AntibodyDiscovery #AI #Biologics #ADC #Bispecific #Oncology #Immunology #Neuroscience #MetabolicDisease
About Harbour BioMed
Harbour BioMed is a global platform-based biopharmaceutical company advancing the discovery and development of breakthrough medicines through proprietary technologies, AI-enabled innovation, and global collaboration. Our proprietary technologies—including Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform, and the Hu-mAtrIx™ AI platform—power differentiated pipelines in oncology, immunology, neuroscience, metabolic diseases, and more. Together with scientists and partners worldwide, we are accelerating the journey from discovery to patients.
Verified activity
Signals from Harbour BioMed
3 published signals
Research & Knowledge
Harbour BioMed partner Windward Bio initiated the first Phase 3 study for HBM9378/WIN378 and planned a second Phase 3 trial for H1 2027.
Reported by Harbour BioMed
Research & Knowledge
Harbour BioMed partner Windward Bio announced positive interim results from the Phase 2 POLARIS-1 trial for HBM9378/WIN378.
Reported by Harbour BioMed
Capital & Finance
Harbour BioMed shares have been included in the list of eligible securities under Hong Kong Stock Connect.
Reported by Harbour BioMed